HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke.

Abstract
This review summarizes the numerous reports that have documented the neuroprotective actions of melatonin in experimental models of ischemia/reperfusion injury (stroke). In these investigations, which have used three species (rat, gerbil, and cat), melatonin was universally found to reduce brain damage that normally occurs as a consequence of the temporary interruption of blood flow followed by the reflow of oxygenated blood to the brain. The exogenous administration of melatonin in these experimental stroke models reduced infarct volume, lowered the frequency of apoptosis, increased the number of surviving neurons, reduced reactive gliosis, lowered the oxidation of neural lipids and oxidatively damaged DNA, induced bcl-2 gene expression (the activity of which improves cell survival), upregulated excision repair cross-complementing factor 6 (an essential gene for preferential DNA excision repair), restrained poly(ADP ribose) synthetase (which depletes cellular NAD resulting in the loss of ATP) activity, and improved neurophysiologic outcomes. Under no circumstances did melatonin exacerbate the damage associated with ischemia/reperfusion injury. As well as the beneficial pharmacologic actions of melatonin, several studies show that a relative deficiency of endogenous melatonin exaggerates neural damage due to stroke; this suggests that even physiologic concentrations of melatonin normally serve to protect the brain against damage. The primary action to explain melatonin's protective effects may relate to its ubiquitous direct and indirect antioxidative actions, although other beneficial functions of melatonin are not precluded.
AuthorsRussell J Reiter, Rosa M Sainz, Silvia Lopez-Burillo, Juan C Mayo, Lucien C Manchester, Dun Xian Tan
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 993 Pg. 35-47; discussion 48-53 (May 2003) ISSN: 0077-8923 [Print] United States
PMID12853293 (Publication Type: Journal Article, Review)
Chemical References
  • Antioxidants
  • Neuroprotective Agents
  • Melatonin
Topics
  • Animals
  • Antioxidants (metabolism, therapeutic use)
  • Brain (metabolism, pathology)
  • Brain Ischemia (drug therapy, pathology, physiopathology)
  • Disease Models, Animal
  • Humans
  • Melatonin (metabolism, therapeutic use)
  • Neuroprotective Agents (metabolism, therapeutic use)
  • Stroke (drug therapy, pathology, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: